代谢相关脂肪性肝病合并2型糖尿病的研究进展

doi:10.13438/j.cnki.jdzk.2024.03.013

吉首大学学报（自然科学版） ›› 2024, Vol. 45 ›› Issue (3): 91-96.DOI: 10.13438/j.cnki.jdzk.2024.03.013

• 经济 • 上一篇

代谢相关脂肪性肝病合并2型糖尿病的研究进展

李园，向平，李学锋，彭霞

（1.吉首大学医学院，湖南吉首 416000；2.湘西土家族苗族自治州人民医院，湖南吉首 416000）

出版日期:2024-05-25 发布日期:2024-06-19
通讯作者: 向平（1964—），男，湖南吉首人，湘西自治州人民医院主任医师，硕士生导师，主要从事消化内科学临床研究.
作者简介:李园（1996—），女，湖南常德人，吉首大学医学院院硕士研究生，主要从事消化内科学临床研究

Advances in Metabolic Related Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus

LI Yuan,XIANG Ping,LI Xuefeng,PENG Xia

(1.School of Medicine,Jishou University,Jishou 416000,Hunan China;2.Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital,Jishou 416000,Hunan China)

Online:2024-05-25 Published:2024-06-19

摘要/Abstract

摘要：代谢相关脂肪性肝病（Metabolic Associated Fatty Liver Disease,MAFLD）与2型糖尿病（Type 2 Diabetes Mellitus,T2DM）的发病率在全球范围内呈现高流行的趋势，超过70%的T2DM患者可能罹患MAFLD，而MAFLD患者患糖尿病的风险比普通人高出约5倍，二者严重威胁人类健康.当MAFLD合并T2DM时，T2DM病情更难控制，MAFLD也更容易恶化，患者罹患心血管疾病、恶性肿瘤的几率更高，死亡风险更大.本文主要对MAFLD合并T2DM的流行病学、发病机制、危险因素及治疗方法进行系统阐述，旨在提升对MAFLD合并T2DM的认识，以更好地指导临床诊治.

关键词： 代谢相关脂肪性肝病, 2型糖尿病, 胰岛素抵抗

Abstract: Metabolic Associated Fatty Liver Disease (MAFLD) and Type 2 Diabetes Mellitus (T2DM) are highly prevalent worldwide.More than 70% of patients with T2DM may develop MAFLD,and patients with MAFLD have a risk of diabetes that is about 5 times higher than the general population,both of which are serious threats to human health.When MAFLD is combined with T2DM,it is more difficult to control T2DM,MAFLD is more likely to deteriorate,and patients have a higher incidence of cardiovascular disease,malignant tumors,and a greater risk of death.In this study,the epidemiology,pathogenesis,risk factors and treatment methods of MAFLD complicated with T2DM are systematically described,aiming to improve the understanding of MAFLD complicated with T2DM and provide better guidance for clinical diagnosis and treatment.

Key words: metabolism-related fatty liver disease, type 2 diabetes, insulin resistance

李园, 向平, 李学锋, 彭霞. 代谢相关脂肪性肝病合并2型糖尿病的研究进展[J]. 吉首大学学报（自然科学版）, 2024, 45(3): 91-96.

LI Yuan, XIANG Ping, LI Xuefeng, PENG Xia. Advances in Metabolic Related Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus[J]. Journal of Jishou University(Natural Sciences Edition), 2024, 45(3): 91-96.

参考文献

[1] 曾静,范建高.非酒精性脂肪性肝病更名的临床意义[J].临床肝胆病杂志,2020,36(6):1205-1207.
[2] 刘英,崔珊珊,暴素青,等.代谢相关性脂肪性肝病与代谢综合征的研究[J].医学信息,2022,35(1):1-5.
[3] LIM SOO,KIM JIN-WOOK,TARGHER GIOVANNI.Links Between Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease[J].Trends Endocrinol Metab,2021,32(7):500-514.
[4] ESLAM MOHAMMED,SANYAL ARUN J,GEORGE JACOB.MAFLD:A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J].Gastroenterology,2020,158(7):1999-2014.
[5] CAUSSY CYRIELLE,AUBIN ADRIEN,LOOMBA ROHIT.The Relationship Between Type 2 Diabetes,NAFLD,and Cardiovascular Risk[J].Current Diabetes Reports,2021,21(5):15.DOI:10.1007/s11892-021-01383-7.
[6] XIAO Jia,WANG Fei,WONG Naikei,et al.Global Liver Disease Burdens and Research Trends:Analysis from a Chinese Aerspective[J].Journal of Hepatology,2019,71(1):212-221.
[7] ZHENG Yan,LEY SYLVIA H,HU FRANK B.Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications[J].Nature Reviews Endocrinology,2018,14(2):88-98.
[8] DAVIS TIMOTHY M E.Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease[J].Metabolism,2021,123(10):186-188.
[9] ESLAM MOHAMMED,NEWSOME PHILIP N,SARIN SHIV K,et al.A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease:An International Expert Consensus Statement[J].Journal of Hepatology,2020,73(1):202-209.
[10] MORIOEI MARIO LUCA,TARGHER GIOVANNI,LAPOLLA ANNUNZIATA,et al.Changes in Markers of Hepatic Steatosis and Fibrosis in Patients with Type 2 Diabetes During Treatment with Glucagon-Like Peptide-1 Receptor Agonists.A multicenter Retrospective Longitudinal Study[J].Nutrition Metabolism and Cardiovascular Diseases,2021,31(12):3474-3483.
[11] 刘勤,牛春燕.由“二次打击”到“多重打击”:发病机制的演变带给非酒精性脂肪性肝病的治疗启示[J].世界华人消化杂志,2019,27(19):1171-1178.
[12] MERONI MARICA,MIRIAM LONGO,RUSTICHELLI ALICE,et al.Nutrition and Genetics in NAFLD:The Perfect Binomium[J].International Journal of Molecular Sciences,2020,21(8):2986.DOI:10.3390/ijms21082986.
[13] KUCHAY MOHAMMAD SHAFI,MISHRA SUNIL KUMAR,CHOUDHARY NARENDRA SINGH,et al.Pathophysiological Mechanisms Underlying MAFLD[J].Diabetes Metabolic Syndrome,2020,14(6):1875-1887.
[14] ABDELAEK MANAL F.Nonalcoholic Fatty Liver Disease:Another Leap Forward[J].Nature Reviews Gastroenterology and Hepatology,2021,18(2):85-86.
[15] IPSEN DAVID HJLAND,LYKKESFELDT JENS,TVEDEN-NYBORG PERNILE.Molecular Mechanisms of Hepatic Lipid Accumulation in Non-Alcoholic Fatty Liver Disease[J].Celluar and Mololecular Life Sciences,2018,75(18):3313-3327.
[16] MUNDI MANPREET S,VELAPATI SAKETH,PATEL JANKI,et al.Evolution of NAFLD and Its Management[J].Nutrition in Clinical Practice,2020,35(1):72-84.
[17] 姚诚子,冯巩,宇文思,等.非酒精性脂肪性肝病发生及进展的危险因素[J].临床肝胆病杂志,2020,36(2):433-436.
[18] ESLAM MOHAMMED,GEORGE JACOB.MAFLD:Now is the Time to Capitalize on the Momentum[J].Journal of Hepatology,2021,74(5):1262-1263.
[19] 刘鹏举,马方,楼慧萍,等.脂肪肝危险因素与脂肪肝严重程度的相关因素分析[J].中华肝脏病杂志,2009,17(9):697-698.
[20] 宋素菲.基于代谢组学研究高脂诱导MAFLD模型大鼠血清脂质特征[J].医学研究生学报,2022,35(5):455-459.
[21] USLU ALI UGUR,SEKIN YAHYA,TARHAN GULTEN,et al.Evaluation of Monocyte to High-Density Lipoprotein Cholesterol Ratio in the Presence and Severity of Metabolic Syndrome[J].Clinical and Applied Thrombosis Hemostasia,2018,24(5):828-833.
[22] 杨丽弘,廖鑫,张晗,等.2型糖尿病合并非酒精性脂肪肝肝纤维化与血清25-羟维生素D水平的关系研究[J].中国糖尿病杂志,2018,26(2):117-122.
[23] 李玲.体检者血清25(OH)D与非酒精性脂肪肝的相关性分析[J].内蒙古医学杂志,2021,53(7):776-779.
[24] MATTOVANI ALESSANDRO,DALBNI ANDREA.Treatments for NAFLD:State of Art[J].International Journal of Molecular Sciences,2021,22(5):235-238.
[25] 曾胜澜,王娜,张荣臻,等.代谢相关脂肪性肝病的治疗研究进展[J].中西医结合肝病杂志,2022,32(3):285-288.
[26] RAZA SANA,RJIAK SANGAM,UPADHYAY ADITYA,et al.Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH[J].Frontiers Bioscience,2021,26(2):206-237.
[27] DE OLIVEIRA SOFIA,HOUSERIGT RUTH A,GRAVES ALYSSA L,et al.Metformin Modulates Innate Immune-Mediated Inflammation and Early Progression of NAFLD-Associated Hepatocellular Carcinoma in Zebrafish[J].Journal of Hepatology,2019,70(4):710-721.
[28] ZHAO Xuanye,LIU Yaoji,LIU Jingjin,et al.Therapeutic Effects and Mechanism of Liraglutide on Rats with Type 2 Diabetes and Metabolic-Associated Fatty Liver Disease[J].Endocrine Metabolic Immune Disorder Drug Targets,2022,26(2):110-115.
[29] CIARDULLO STEFANO,PESERGHIN GIANLUCA.Statin Use is Associated with Lower Prevalence of Advanced Liver Fibrosis in Patients with Type 2 Diabetes[J].Metabolism Clinical and Experimental,2021,121(8):154-158.
[30] WANG Wei,XU Ailei,LI Zhengchao,et al.Combination of Probiotics and Salvia Miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice[J].Diabetes and Metabolism Journal,2020,44(2):336-348.
[31] 范尧夫,曹琳,孙洪平,等.葛根芩连汤治疗2型糖尿病合并非酒精性脂肪性肝病效果的临床研究[J].中国全科医学,2021,24(36):4587-4592.
[32] IKRAMUDDIN SAYEED,KORNER JUDITH,LEE WEI-JEI,et al.Lifestyle Intervention and Medical Management with vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c,LDL Cholesterol,and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study[J].The Journal of the American Medical Association,2018,319(3):266-278.

代谢相关脂肪性肝病合并2型糖尿病的研究进展

Advances in Metabolic Related Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价